Rusk et al v. Novartis Pharmaceuticals Corporation et al
||John Anthony Rusk and Judy Rusk
||Barr Laboratories, Inc., Eon Labs, Inc., Novartis Pharmaceuticals Corporation, Sandoz Pharmaceuticals Corporation, Teva Pharmaceuticals USA Inc. and Wyeth-Ayerst Laboratories, Inc.
||June 11, 2014
||US District Court for the Western District of Texas
|Nature of Suit:
||Personal Injury: Health Care
|Cause of Action:
||28:1332 Diversity-Petition for Removal
|Jury Demanded By:
Access additional case information on PACER
Available Case Documents
The following documents for this case are available for you to view or download:
|June 11, 2015
REPORT AND RECOMMENDATIONS that Defendants 21 Motion to Dismiss be GRANTED WITHOUT PREJUDICE. It is further RECOMMENDED that Plaintiffs Motion for Leave to Amend be GRANTED. Specifically, the undersigned RECOMMENDS that Plaintiffs be granted leave to amend only their claims for wrongful off-label promotion and failure to supply adequate Medication Guides, as the remainder of their claims for relief related to the manufacture, marketing, distribution, and sale of amniodarone, Compl. at 131, are preempted as a matter of law. Signed by Judge Mark Lane. (klw)
Use the links below to access additional information about this case on the US Court's PACER system.
A subscription to PACER is required.
Access this case on the Texas Western District Court's Electronic Court Filings (ECF) System
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?